AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
175.18
-2.71 (-1.52%)
Jun 18, 2026, 2:38 PM EDT - Market open
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
Oncology Revenue | 26.77B | 25.62B | 20.28B | ||||||||||||
Oncology Revenue Growth | 4.50% | 26.35% | 18.26% | ||||||||||||
BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM) Revenue | 12.77B | 12.77B | 12.45B | ||||||||||||
BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM) Revenue Growth | -0.06% | 2.62% | 17.60% | ||||||||||||
BioPharmaceuticals: Respiratory & Immunology PR (R&I) Revenue | 9.10B | 8.87B | 7.42B | ||||||||||||
BioPharmaceuticals: Respiratory & Immunology PR (R&I) Revenue Growth | 2.64% | 19.55% | 21.43% | ||||||||||||
BioPharmaceuticals Infectious Disease PR (ID) Revenue | 1.23B | 1.27B | 1.06B | ||||||||||||
BioPharmaceuticals Infectious Disease PR (ID) Revenue Growth | -3.39% | 19.85% | 4.54% | ||||||||||||
Rare Disease Revenue | 9.50B | 9.13B | 8.67B | ||||||||||||
Rare Disease Revenue Growth | 4.14% | 5.28% | 11.64% | ||||||||||||
Other Medicines Revenue | 969.00M | 988.00M | 1.07B | ||||||||||||
Other Medicines Revenue Growth | -1.92% | -7.92% | -8.76% | ||||||||||||
Collaboration Revenue | 102.00M | 99.00M | 3.14B | ||||||||||||
Collaboration Revenue Growth | 3.03% | -96.84% | 55.05% | ||||||||||||
Revenue (Total) | 60.44B | 58.74B | 54.07B | ||||||||||||
Revenue (Total) Growth | 2.89% | 8.63% | 18.04% |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
UK Revenue | - | 4.36B | 4.74B | ||||||||||||
UK Revenue Growth | - | -8.04% | 40.74% | ||||||||||||
Rest of Europe Revenue | - | 13.46B | 11.70B | ||||||||||||
Rest of Europe Revenue Growth | - | 14.97% | 20.34% | ||||||||||||
The Americas Revenue | - | 27.56B | 24.99B | ||||||||||||
The Americas Revenue Growth | - | 10.28% | 20.31% | ||||||||||||
Asia, Africa & Australasia Revenue | - | 13.37B | 12.64B | ||||||||||||
Asia, Africa & Australasia Revenue Growth | - | 5.75% | 5.81% | ||||||||||||
Revenue (Total) | 60.44B | 58.74B | 54.07B | ||||||||||||
Revenue (Total) Growth | 2.89% | 8.63% | 18.04% |
EBIT by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
UK Operating Profit | - | 7.07B | 2.68B | ||||||||||||
UK Operating Profit Growth | - | 163.66% | 303.01% | ||||||||||||
Rest of Europe Operating Profit | - | 5.23B | 5.92B | ||||||||||||
Rest of Europe Operating Profit Growth | - | -11.66% | 21.27% | ||||||||||||
The Americas Operating Profit | - | 440.00M | 423.00M | ||||||||||||
The Americas Operating Profit Growth | - | 4.02% | -71.71% | ||||||||||||
Asia, Africa & Australasia Operating Profit | - | 1.00B | 976.00M | ||||||||||||
Asia, Africa & Australasia Operating Profit Growth | - | 2.87% | -14.98% | ||||||||||||
Operating Income (Total) | 14.32B | 13.74B | 10.00B | ||||||||||||
Operating Income (Total) Growth | 4.16% | 37.39% | 22.09% |
Capital Expenditures by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
UK Assets Acquired | 1.76B | 582.00M | ||||||||||||
UK Assets Acquired Growth | 202.23% | -28.32% | ||||||||||||
Rest of Europe Assets Acquired | 2.81B | 2.23B | ||||||||||||
Rest of Europe Assets Acquired Growth | 26.47% | 25.71% | ||||||||||||
The Americas Assets Acquired | 1.88B | 3.93B | ||||||||||||
The Americas Assets Acquired Growth | -52.18% | 103.90% | ||||||||||||
Asia, Africa & Australasia Assets Acquired | 557.00M | 1.39B | ||||||||||||
Asia, Africa & Australasia Assets Acquired Growth | -60.04% | 1091.45% |